

Mark John Field

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7368126/mark-john-field-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

23
papers

2,509
citations

20
h-index

25
g-index

25
ext. papers

2,674
ext. citations

7
avg, IF

4.04
L-index

#	Paper	IF	Citations
23	Validity of the cold pressor test and pain sensitivity questionnaire via online self-administration. <i>PLoS ONE</i> , 2020 , 15, e0231697	3.7	4
22	Accurate pain reporting training diminishes the placebo response: Results from a randomised, double-blind, crossover trial. <i>PLoS ONE</i> , 2018 , 13, e0197844	3.7	25
21	Identification of patients with neuropathic pain using electronic primary care records. <i>Journal of Innovation in Health Informatics</i> , 2011 , 19, 83-90		7
20	Population pharmacokinetic model of the pregabalin-sildenafil interaction in rats: application of simulation to preclinical PK-PD study design. <i>Pharmaceutical Research</i> , 2009 , 26, 2259-69	4.5	12
19	Ca ²⁺ channel alpha2-delta ligands for the treatment of neuropathic pain. <i>Journal of Medicinal Chemistry</i> , 2007 , 50, 2569-75	8.3	55
18	Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 17537-42	11.5	442
17	Structure-activity relationships of pregabalin and analogues that target the alpha(2)-delta protein. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 2294-307	8.3	170
16	The monosodium iodoacetate model of osteoarthritis: a model of chronic nociceptive pain in rats?. <i>Neuroscience Letters</i> , 2004 , 370, 236-40	3.3	168
15	Pregabalin may represent a novel class of anxiolytic agents with a broad spectrum of activity. <i>British Journal of Pharmacology</i> , 2001 , 132, 1-4	8.6	70
14	Utilization of an intramolecular hydrogen bond to increase the CNS penetration of an NK(1) receptor antagonist. <i>Journal of Medicinal Chemistry</i> , 2001 , 44, 2276-85	8.3	70
13	Further evidence for the role of the alpha(2)delta subunit of voltage dependent calcium channels in models of neuropathic pain. <i>British Journal of Pharmacology</i> , 2000 , 131, 282-6	8.6	87
12	Ovariohysterectomy in the rat: a model of surgical pain for evaluation of pre-emptive analgesia?. <i>Pain</i> , 2000 , 88, 79-88	8	27
11	Enadoline, a selective kappa-opioid receptor agonist shows potent antihyperalgesic and antiallodynic actions in a rat model of surgical pain. <i>Pain</i> , 1999 , 80, 383-9	8	28
10	Gabapentin and pregabalin, but not morphine and amitriptyline, block both static and dynamic components of mechanical allodynia induced by streptozocin in the rat. <i>Pain</i> , 1999 , 80, 391-8	8	239
9	Detection of static and dynamic components of mechanical allodynia in rat models of neuropathic pain: are they signalled by distinct primary sensory neurones?. <i>Pain</i> , 1999 , 83, 303-11	8	155
8	Novel nonpeptide CCK-B antagonists: design and development of quinazolinone derivatives as potent, selective, and orally active CCK-B antagonists. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 1042-9	8.3	75
7	Second generation "peptoid" CCK-B receptor antagonists: identification and development of N-(adamantylloxycarbonyl)-alpha-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. <i>Journal of Medicinal Chemistry</i> , 1998 , 41, 38-45	8.3	37

6	Gabapentin (neurontin) and S-(+)-3-isobutylgaba represent a novel class of selective antihyperalgesic agents. <i>British Journal of Pharmacology</i> , 1997 , 121, 1513-22	8.6	260
5	The anxiolytics CI-988 and chlordiazepoxide fail to reduce immediate early gene mRNA stimulation following exposure to the rat elevated X-maze. <i>European Journal of Pharmacology</i> , 1996 , 312, 153-61	5.3	33
4	The antiepileptic agent gabapentin (Neurontin) possesses anxiolytic-like and antinociceptive actions that are reversed by D-serine. <i>Psychopharmacology</i> , 1996 , 127, 1-9	4.7	195
3	Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 1130-3	11.5	166
2	The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. <i>British Journal of Pharmacology</i> , 1991 , 104, 239-45	8.6	120
1	Comparison of the effects of four cholinomimetic agents on cognition in primates following disruption by scopolamine or by lists of objects. <i>Psychopharmacology</i> , 1989 , 99, 189-95	4.7	64